SIGA Technologies shares are trading lower after the National Institutes of Health's National Institute of Allergy and Infectious Diseases announced topline results from a preliminary analysis of the PALM 007 trial of Tecovirimat for Mpox virus did not meet its primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
SIGA Technologies shares are trading lower after the National Institutes of Health's National Institute of Allergy and Infectious Diseases announced that the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.
August 15, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
SIGA Technologies shares are trading lower due to the NIH's announcement that the PALM 007 trial of Tecovirimat for Monkeypox virus did not meet its primary endpoint.
The failure of the PALM 007 trial to meet its primary endpoint is a significant setback for SIGA Technologies, as it directly impacts the potential success and marketability of Tecovirimat for treating Monkeypox virus. This negative news is likely to result in a short-term decline in SIGA's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100